Neoplasm, Residual clinical trials

The registry lists 293 studies for Neoplasm, Residual across more than 10 countries. 137 are recruiting or about to start. 53 of them are mainly about Neoplasm, Residual (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Neoplasm, Residual studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting: 92
Completed: 64
Not yet recruiting: 43
Active, not recruiting: 33
Status unknown: 27
Terminated: 21

Phase

Phase 2: 117
Phase 1: 48
Phase 3: 21
Phase 4: 7
Early Phase 1: 4

Where

United States: 86
China: 78
France: 31
Germany: 23
Italy: 21
Spain: 19

Who runs them

Peking University People's Hospital (15) · Institute of Hematology & Blood Diseases Hospital, China (11) · M.D. Anderson Cancer Center (10) · Nanfang Hospital, Southern Medical University (7) · National Cancer Institute (NCI) (6) · Assistance Publique - Hôpitaux de Paris (5) · Novartis Pharmaceuticals (5) · PETHEMA Foundation (4)

What is being tested here

Drugs under test in Neoplasm, Residual studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Venetoclax	5	1	9
Azacitidine	4	0	9
Daratumumab	4	0	5
Blinatumomab	3	0	17
Fludarabine	3	1	11
Cyclophosphamide	2	0	7
Cytarabine	2	2	7
Dexamethasone	2	0	5
Idarubicin	2	0	3
Carboplatin	2	0	3

Drug classes tested here Antimetabolites 10 open · Immune checkpoint inhibitors 9 open · Tyrosine kinase inhibitors (TKIs) 6 open · Antibody-drug conjugates (ADCs) 6 open · HDAC inhibitors 3 open

Coming up

11phase 3 studies under way

46studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study · Phase 3 · Nanfang Hospital, Southern Medical University
Apr 2027VEN+IDAC vs IDAC in AML · Phase 3 · Guangdong Second Provincial General Hospital
Nov 2026Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer · Stanford University
Nov 2026Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer · JaxBio Ltd
Nov 2026Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults · PETHEMA Foundation
Dec 2026MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment · Invitae Corporation
Dec 2026DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma · Institute of Hematology & Blood Diseases Hospital, China
Dec 2026A Study of Chidamide With AZA in MRD Positive AML After Transplant · Guangdong Provincial People's Hospital
Dec 2026Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer · Anhui Medical University
Dec 2026Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) · Dana-Farber Cancer Institute

Who these studies take

Of the 92 Neoplasm, Residual studies recruiting now, 58 (63%) set no upper age limit and 23 (25%) stop at 75 or younger. 19 (21%) take children under 18. 3 (3%) are for women only and 1 (1%) for men only; 7 (8%) take healthy volunteers.

Recruiting studies that take each age, of 92
Age	Women	Men
10	12 (13%)	12 (13%)
18	88 (96%)	86 (93%)
30	89 (97%)	87 (95%)
40	88 (96%)	86 (93%)
50	88 (96%)	86 (93%)
65	84 (91%)	82 (89%)
75	74 (80%)	72 (78%)
85	61 (66%)	59 (64%)

Across all 293 studies, recruiting or not: 29% stop at 75 or younger and 16% at 65; 24% take children; 6% are for women only and 1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neoplasm, Residual studies take

Of 52 phase 2 interventional studies under Neoplasm, Residual, half reached primary completion within 71 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	70 mo32–89 · 20 studies	—	—
Phase 2	71 mo50–120 · 52 studies	—	66 mo50–94 · 49 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC PatientsNov 4, 2026NCT07709585

Newly registered11

Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Bladder Tumour for Prediction of Muscle Invasion and Detection of Residual Tumour in Non-muscle-invasive Bladder Cancer PatientsNov 9, 2026NCT07924046
Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNANov 6, 2026NCT07921888
Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCTNov 5, 2026NCT07919119
Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaOct 28, 2026NCT07901868
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid LeukemiaOct 27, 2026NCT07897136

Show 6 more

MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung CancerOct 26, 2026NCT07894458
MRD Monitoring in Colorectal Cancer Using ctDNAOct 26, 2026NCT07895459
Comparison of Outcomes of Microscopic Mastoidectomy With and Without Check EndoscopyOct 26, 2026NCT07896200
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple MyelomaOct 23, 2026NCT07891923
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCOct 21, 2026NCT07885709
MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLCOct 14, 2026NCT07873086

Studies

Recruiting first, then most recently updated. Showing 50 of 293. Browse all 293 → or search them.